Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. HOOD
8. DFTX
9. USO
10. RGNX

Go back to Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
(NYSE: ATH) Delayed: 83.33 --0 (-0%)
Previous Close $83.33    52 Week High $ 
Open $83.33    52 Week Low $ 
Day High $83.33    P/E N/A 
Day Low $83.33    EPS $ 
Volume 7,858       

(NASDAQ: ATHE) Delayed: 4.90 +0.02 (0.41%)
Previous Close $4.88    52 Week High $ 
Open $4.92    52 Week Low $ 
Day High $4.94    P/E N/A 
Day Low $4.90    EPS $ 
Volume 4,232